BioPorto wraps up enrollment ahead of summer NDA
BioPorto has finished enrollment of patients for a pivotal study of the company’s NGAL test. BioPorto aims to submit an application in the summer with expected approval as early as this year.
BY BENJAMIN WERNER CHRISTENSEN
Danish-based diagnostics company BioPorto has completed the enrollment of patients for the clinical trial, which secures the data which will be part of the US submission of The NGAL Test to be submitted during the summer, the company writes in a press release.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
BioPorto expects fast US penetration
For abonnenter
BioPorto denies rumors in the market
For abonnenter
BioPorto CFO switches to Novo-owned company
For abonnenter
